GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (LTS:0UP6) » Definitions » Loans Receivable

Novavax (LTS:0UP6) Loans Receivable : $0 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Novavax Loans Receivable?

Novavax's Loans Receivable for the quarter that ended in Mar. 2024 was $0 Mil.


Novavax Loans Receivable Historical Data

The historical data trend for Novavax's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Loans Receivable Chart

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novavax Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novavax Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Novavax Loans Receivable Related Terms

Thank you for viewing the detailed overview of Novavax's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (LTS:0UP6) Business Description

Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (LTS:0UP6) Headlines

No Headlines